Faculty of Medicine Gynecological Oncology Surgery, Uludag University, Bursa 16059, Turkey.
Faculty of Medicine Gynecological Oncology Surgery, Uludag University, Bursa 16059, Turkey.
J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102642. doi: 10.1016/j.jogoh.2023.102642. Epub 2023 Aug 11.
Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion which is located in the distal fallopian tube and causes high grade serous ovarian carcinoma (HGSOC). The incidence of STIC for women underwent risk reducing salpingo-oophorectomy for BRCA mutation varies from 0.6 to 7% and its clinical outcomes are still unclear. The aim of this study was to demonstrate the incidence of STIC and HGSOC in BRCA1/2 mutation carriers after risk reducing salpingo-oophorectomy (RRSO) and the clinical outcomes of these patients.
We retrospectively reviewed the records of 48 BRCA1 and/or 2 mutation carriers who underwent prophylactic salpingo-oophorectomy with or without hysterectomy at the Department of Obstetrics and Gynecology, Bursa Uludag University between January 2000 and January 2022.
BRCA 1 and/or 2 mutation carriers diagnosed by genetic testing, asymptomatic patients with no abnormal findings on pelvic examination.
patients with no abnormal findings on pelvic examination and a presence of a personal history of ovarian, fallopian tube or peritoneal cancer.
A total of 48 BRCA 1 and/or 2 mutation carriers underwent RRSO. STIC was diagnosed in 1 (2,0%) patient and restaging surgery was not performed. Primary peritoneal carcinoma (PPC) did not develop during the 20 months follow-up period. One (2.0%) patient was diagnosed with occult ovarian cancer. Restaging surgery was performed and chemotherapy treatments were given after surgery. A pelvic recurrence developed 25 months after the occult cancer diagnosis in the follow up period. One (2.0%) patient with normal histopathological findings after RRSO was diagnosed with peritoneal cancer 57 months after the operation.
The risk of PPC continues after RRSO. Therefore, close follow-up procedure is very important for early diagnosis and effective treatment of patients with PPC after RRSO.
输卵管上皮内浆液性癌(STIC)是一种位于输卵管远端的癌前病变,可导致高级别浆液性卵巢癌(HGSOC)。接受 BRCA 基因突变风险降低输卵管卵巢切除术(RRSO)的女性中 STIC 的发病率为 0.6%至 7%,其临床结果尚不清楚。本研究旨在展示 BRCA1/2 基因突变携带者 RRSO 后 STIC 和 HGSOC 的发生率以及这些患者的临床结果。
我们回顾性分析了 2000 年 1 月至 2022 年 1 月在布尔萨乌鲁达大学妇产科接受预防性输卵管卵巢切除术(伴或不伴子宫切除术)的 48 名 BRCA1 和/或 2 基因突变携带者的记录。
通过基因检测诊断为 BRCA 1 和/或 2 基因突变携带者,无症状,盆腔检查无异常。
盆腔检查无异常,无卵巢、输卵管或腹膜癌个人病史。
共有 48 名 BRCA 1 和/或 2 基因突变携带者接受了 RRSO。1 名(2.0%)患者诊断为 STIC,未行再次分期手术。在 20 个月的随访期间未发生原发性腹膜癌(PPC)。1 名(2.0%)患者被诊断为隐匿性卵巢癌。行再次分期手术,术后给予化疗。在随访期间,隐匿性癌症诊断后 25 个月出现盆腔复发。1 名(2.0%)RRSO 后组织病理学检查正常的患者在手术后 57 个月被诊断为腹膜癌。
RRSO 后 PPC 的风险仍持续存在。因此,RRSO 后密切随访对 PPC 患者的早期诊断和有效治疗非常重要。